Oramed Pharmaceuticals Inc. / Fundamentals
Income statement
- Net revenue
€1.72M - Cost of goods sold
€1.76M - Gross profit
-€41.18K - SG&A expenses
€5.79M - R&D expenses
€5.96M - EBITDA
-€3.51M - D&A
€122.69K - EBIT
-€11.73M - Interest expenses
€2.19M - EBT
-€19.06M - Tax expenses
€1.72M - Net income
-€20.73M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€5.20M - Changes in working capital
-€2.20M - Operating cash flow
-€13.78M - Capex
€19.73K - Other investing cash flow
€76.42M - Net investing cash flow
-€42.96M - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€42.17M - Other financing cash flow
-€42.17M - Net financing cash flow
-€2.45M - Foreign exchange effects
€34.32K - Net change in cash
-€59.16M - Cash at end of period
€13.55M - Free cash flow
-€13.76M
Balance sheet
- Cash and cash equivalents
€13.55M - Cash and short-term investments
€84.03M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€931.79K - Total current assets
€84.96M - Property, plant & equipment
€2.98M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€48.57M - Other non-current assets
€2.20M - Total non-current assets
€53.76M - Total assets
€138.73M - Accounts payable
€613.47K - Short-term debt
€226.51K - Other current liabilities
€972.97K - Total current liabilities
€3.17M - Long-term debt
€555.98K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€30.89K - Total non-current liabilities
€3.78M - Total liabilities
€6.95M - Common stock
€421.28K - Retained earnings
-€146.69M - Other equity
€0.00 - Total equity
€131.77M - Total liabilities and shareholders' equity
€138.73M
Company information
- Market capitalization
€74.91M - Employees
13 - Enterprise Value
€49.42M
Company ratios
- Gross margin
-
-2.4% Much worse than peer group: 10,395,157,044,799,896,000.0% - EBITDA margin
-
-204.8% Much worse than peer group: 1,003,720,353,005,739,200.0% - EBIT margin
-
-683.7% Much worse than peer group: 860,654,072,439,453,700.0% - EBT margin
-
-1,110.8% Much worse than peer group: 1,051,767,481,767,295,600.0% - Net margin
-
-1,208.1% Much worse than peer group: 1,051,767,481,767,231,400.0% - ROE
-
-15.7% Much better than peer group: -2,388.6% - ROA
-
-14.9% Much better than peer group: -285.8% - Asset turnover
-
1.2% Much worse than peer group: 249,427.8% - FCF margin
-
-804.5% Much worse than peer group: 595,818,011,889,303,000.0% - FCF yield
-18.4% - Efficiency ratio
304.8% - Net sales per employee
-
€132.00K - Net income per employee
-
-€1.59M